Market closed

BioXcel Therapeutics/$BTAI

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About BioXcel Therapeutics

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Ticker

$BTAI
Trading on

Industry

Biotechnology

Employees

74

BTAI Metrics

BasicAdvanced
$13M
Market cap
-
P/E ratio
-$1.99
EPS
-0.03
Beta
-
Dividend rate
$13M
-0.03
$4.17
$0.32
825K
1.87
1.58
-122.15
-122.58
-5.11%
-62.12%
112.48%
4.954
-0.16
-0.16
-0.134
83.25%
-72.98%
-20.82%

What the Analysts think about BTAI

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for BioXcel Therapeutics stock.

BTAI Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BTAI Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BTAI

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BioXcel Therapeutics stock?

BioXcel Therapeutics (BTAI) has a market cap of $13M as of December 21, 2024.

What is the P/E ratio for BioXcel Therapeutics stock?

The price to earnings (P/E) ratio for BioXcel Therapeutics (BTAI) stock is 0 as of December 21, 2024.

Does BioXcel Therapeutics stock pay dividends?

No, BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next BioXcel Therapeutics dividend payment date?

BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders.

What is the beta indicator for BioXcel Therapeutics?

BioXcel Therapeutics (BTAI) has a beta rating of -0.03. This means that it has an inverse relation to market volatility.